The expression of CD200 and CD23 on B lymphocytes in the pollen season and outside the pollen season in atopic dermatitis patients with and without dupilumab therapy

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00179906%3A_____%2F24%3A10474400" target="_blank" >RIV/00179906:_____/24:10474400 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11150/24:10474400

Výsledek na webu

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=vRfY32bz7K" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=vRfY32bz7K</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1080/09546634.2024.2305832" target="_blank" >10.1080/09546634.2024.2305832</a>

Jazyk výsledku

angličtina

Název v původním jazyce

The expression of CD200 and CD23 on B lymphocytes in the pollen season and outside the pollen season in atopic dermatitis patients with and without dupilumab therapy

Popis výsledku v původním jazyce

The expression of CD23 and CD200 molecules on B lymphocytes and on their subsets in atopic dermatitis (AD) patients (with and without dupilumab therapy) and in healthy subjects was evaluated in pollen season and out of pollen season. 21 AD patients without dupilumab treatment and 13 AD patients treated with dupilumab and control groups were included in the study. CD23 and CD200 expression on B lymphocytes was evaluated with flow cytometry. During pollen season there is a significant decrease in expression of CD200 on memory, naive, non switched and total CD200 B lymhocytes in AD patients without dupilumab therapy, a significant increase of expression CD23 on naive B lymphocytes in AD patients with dupilumab therapy and a significant increase of expression CD23 on switched B lymphocytes in control group. In conclusion, the results of our study show that the expression of CD23 and CD200 molecules on B lymphocytes differ in the pollen season and out of pollen season in both patients with atopic dermatitis (treated and not treated with dupilumab) and in the control group. The results of our study suggest that dupilumab affects the expression of CD200 and CD23 on B lymphocytes. When assessing the expression of CD23 and CD200 on B lymphocytes, it is necessary to take into account the period of the year in which the examination was performed.

Název v anglickém jazyce

The expression of CD200 and CD23 on B lymphocytes in the pollen season and outside the pollen season in atopic dermatitis patients with and without dupilumab therapy

Popis výsledku anglicky

The expression of CD23 and CD200 molecules on B lymphocytes and on their subsets in atopic dermatitis (AD) patients (with and without dupilumab therapy) and in healthy subjects was evaluated in pollen season and out of pollen season. 21 AD patients without dupilumab treatment and 13 AD patients treated with dupilumab and control groups were included in the study. CD23 and CD200 expression on B lymphocytes was evaluated with flow cytometry. During pollen season there is a significant decrease in expression of CD200 on memory, naive, non switched and total CD200 B lymhocytes in AD patients without dupilumab therapy, a significant increase of expression CD23 on naive B lymphocytes in AD patients with dupilumab therapy and a significant increase of expression CD23 on switched B lymphocytes in control group. In conclusion, the results of our study show that the expression of CD23 and CD200 molecules on B lymphocytes differ in the pollen season and out of pollen season in both patients with atopic dermatitis (treated and not treated with dupilumab) and in the control group. The results of our study suggest that dupilumab affects the expression of CD200 and CD23 on B lymphocytes. When assessing the expression of CD23 and CD200 on B lymphocytes, it is necessary to take into account the period of the year in which the examination was performed.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30216 - Dermatology and venereal diseases

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2024

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Journal of Dermatological Treatment

ISSN

0954-6634

e-ISSN

1471-1753

Svazek periodika

35

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

6

Strana od-do

2305832

Kód UT WoS článku

001150204800001

EID výsledku v databázi Scopus

2-s2.0-85183340261